Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG10 in healthy subjects
NCT03294707Phase 1Completed
- Sponsor
- BridgeBio Pharma
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) (4 arms), sponsored by BridgeBio Pharma. Primary endpoint: Safety and tolerability at 30 days. Started Sep 2017; status: completed.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT03294707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294707.